Objective: To investigate the value of the naturally occurring serum AIAs of α-synuclein (α-syn) and tau, proteins as potential biomarker for diagnosis of PD in comparison to Alzheimer’s type (AD) and healthy controls.

Background: Early diagnosis of neurodegenerative diseases is of paramount importance for successful treatment. Discovering specific biomarker for Parkinson’s disease (PD) is warranted for early diagnosis and investigating the neuroprotective drugs. Using serum autoimmune antibodies (AIAs) against neural proteins is a new promising strategy to diagnose brain disorders through non-invasive and cost-effective method.

Methods: The study was composed of three groups, 27 AD patients, 46 PD patients, and 20 healthy controls. IgG anti α-syn and tau AIAs have been tested using ELISA, for all subjects.

Results: The median of serum α-syn AIAs was highest in patients with PD [4.23 ng/ml (3.3–5.63)], and elevated in AD [2.9 ng/ml (1.2–3.3)], less than PD patients, while lowest in controls [0.46 ng/ml (0.07–0.93)]. The Median (IQR) of tau in PD patients was 3.91 (3.22 – 5.38), and in Alzheimer’s patients was 8.09 (4.48 – 13.7) while in controls was 0.28 (0 – 0.46). There was high statistical significant difference between the three studied groups regarding level of tau and α-syn (p < 0.001). There was high significant correlation regarding level of both α-syn AIA and tau AIAs (p = 0.008), and between α-syn AIAs and age of PD patients (p value = 0.007).

Conclusions: Serum tau and α-syn AIAs could identify cases with neurodegeneration compared to healthy subjects, which advocates their use for diagnosis of PD.

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/tau-and-%ce%b1-synuclein-autoantibodies-as-potential-biomarkers-for-parkinsons-and-alzheimers-diseases/